Shopping Cart 0
Cart Subtotal
USD 0

4SC AG (VSC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

4SC AG (4SC) is a biopharmaceutical company that discovers and develops small molecule drugs for the treatment of cancer and autoimmune diseases. The company's product focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its product pipeline comprises therapeutic programs at various stages of clinical development and early-stage research projects including Resminostat, 4SC-202 and 4SC-208. The company's research programs are related to cancer stem cells, ion channel blockers and cytokine modulation. It develops and markets products through partnerships with pharmaceutical and biotech companies. The company operates through its subsidiary 4SC Discovery GmbH. 4SC is headquartered in Bayern, Germany.

4SC AG (VSC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

4SC AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

4SC AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

4SC AG, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

4SC Plans To Enters Into Co-Development Agreement For Resminostat 10

4SC Enters Into Co-Development Agreement With Crelux And Ribological 11

Licensing Agreements 12

Maruho Enters into Licensing Agreement with 4SC 12

Link Health Enters into Licensing Agreement with 4SC 13

Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 14

Equity Offering 15

4SC Raises USD46 Million in Rights Offering of Shares 15

4SC Raises USD32 Million in Rights Offering of Shares 16

Debt Offering 17

4SC Raises USD0.6 Million in Second Tranche of Private Placement of Notes 17

Asset Transactions 18

Immunic Acquires Immunology Portfolio from 4SC 18

Acquisition 19

BioNTech Small Molecules Acquires 4SC Discovery from 4SC 19

4SC AG-Key Competitors 20

4SC AG-Key Employees 21

4SC AG-Locations And Subsidiaries 22

Head Office 22

Recent Developments 23

Financial Announcements 23

Mar 21, 2018: 4SC announces results for financial year 2017 23

Aug 10, 2017: 4SC provides Q2 and 6M 2017 update 24

Product News 25

07/31/2018: 4SC announce first patient enrolled in 2nd dose cohort of Phase Ib/II study SENSITIZE of domatinostat (4SC-202) + pembrolizumab in melanoma 25

07/03/2018: Positive safety review of 4SC's Phase Ib/II SENSITIZE study of domatinostat (4SC-202) + pembrolizumab in melanoma 26

06/11/2017: First patient enrolled in Phase Ib/II study SENSITIZE of 4SC-202 in melanoma 27

04/11/2017: New mechanistic insights into 4SC-202's epigenetic mode of action 28

Other Significant Developments 29

Oct 25, 2018: 4SC provides Q3 business update and outlook 29

Oct 26, 2017: 4SC provides Q3 and 9M 2017 update 30

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31


List Of Figure

List of Figures

4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

4SC AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

4SC AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

4SC AG, Deals By Therapy Area, 2012 to YTD 2018 8

4SC AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

4SC Plans To Enters Into Co-Development Agreement For Resminostat 10

4SC Enters Into Co-Development Agreement With Crelux And Ribological 11

Maruho Enters into Licensing Agreement with 4SC 12

Link Health Enters into Licensing Agreement with 4SC 13

Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 14

4SC Raises USD46 Million in Rights Offering of Shares 15

4SC Raises USD32 Million in Rights Offering of Shares 16

4SC Raises USD0.6 Million in Second Tranche of Private Placement of Notes 17

Immunic Acquires Immunology Portfolio from 4SC 18

BioNTech Small Molecules Acquires 4SC Discovery from 4SC 19

4SC AG, Key Competitors 20

4SC AG, Key Employees 21

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

4SC AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

4SC AG (4SC) is a biopharmaceutical company that discovers and develops small molecule drugs for the treatment of cancer and autoimmune diseases. The company's product focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its product pipeline comprises therapeutic programs at various stages of clinical development and early-stage research projects including Resminostat, 4SC-202 and 4SC-208. The company's research programs are related to cancer stem cells, ion channel blockers and cytokine modulation. It develops and markets products through partnerships with pharmaceutical and biotech companies. The company operates through its subsidiary 4SC Discovery GmbH. 4SC is headquartered in Bayern, Germany.

4SC AG (VSC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

4SC AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

4SC AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

4SC AG, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

4SC Plans To Enters Into Co-Development Agreement For Resminostat 10

4SC Enters Into Co-Development Agreement With Crelux And Ribological 11

Licensing Agreements 12

Maruho Enters into Licensing Agreement with 4SC 12

Link Health Enters into Licensing Agreement with 4SC 13

Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 14

Equity Offering 15

4SC Raises USD46 Million in Rights Offering of Shares 15

4SC Raises USD32 Million in Rights Offering of Shares 16

Debt Offering 17

4SC Raises USD0.6 Million in Second Tranche of Private Placement of Notes 17

Asset Transactions 18

Immunic Acquires Immunology Portfolio from 4SC 18

Acquisition 19

BioNTech Small Molecules Acquires 4SC Discovery from 4SC 19

4SC AG-Key Competitors 20

4SC AG-Key Employees 21

4SC AG-Locations And Subsidiaries 22

Head Office 22

Recent Developments 23

Financial Announcements 23

Mar 21, 2018: 4SC announces results for financial year 2017 23

Aug 10, 2017: 4SC provides Q2 and 6M 2017 update 24

Product News 25

07/31/2018: 4SC announce first patient enrolled in 2nd dose cohort of Phase Ib/II study SENSITIZE of domatinostat (4SC-202) + pembrolizumab in melanoma 25

07/03/2018: Positive safety review of 4SC's Phase Ib/II SENSITIZE study of domatinostat (4SC-202) + pembrolizumab in melanoma 26

06/11/2017: First patient enrolled in Phase Ib/II study SENSITIZE of 4SC-202 in melanoma 27

04/11/2017: New mechanistic insights into 4SC-202's epigenetic mode of action 28

Other Significant Developments 29

Oct 25, 2018: 4SC provides Q3 business update and outlook 29

Oct 26, 2017: 4SC provides Q3 and 9M 2017 update 30

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31


List Of Figure

List of Figures

4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

4SC AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

4SC AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

4SC AG, Deals By Therapy Area, 2012 to YTD 2018 8

4SC AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

4SC Plans To Enters Into Co-Development Agreement For Resminostat 10

4SC Enters Into Co-Development Agreement With Crelux And Ribological 11

Maruho Enters into Licensing Agreement with 4SC 12

Link Health Enters into Licensing Agreement with 4SC 13

Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 14

4SC Raises USD46 Million in Rights Offering of Shares 15

4SC Raises USD32 Million in Rights Offering of Shares 16

4SC Raises USD0.6 Million in Second Tranche of Private Placement of Notes 17

Immunic Acquires Immunology Portfolio from 4SC 18

BioNTech Small Molecules Acquires 4SC Discovery from 4SC 19

4SC AG, Key Competitors 20

4SC AG, Key Employees 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

4SC AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.